FOLH1 and prostate adenocarcinoma: Qu et al believe that the SEN and SPE of PET/CT are better than MRI and bone scan.[22] PSMA is overexpressed in most prostatic adenocarcinomas, and its expression levels increase with increasing tumor dedifferentiation in hormone-refractory and metastatic PC.[23,24] At present, small molecule inhibitors often used as the molecular probes of PSMA.